Shares of Demant A/S Unsponsored ADR (OTCMKTS:WILYY – Get Free Report) saw unusually-high trading volume on Tuesday. 5,300 shares traded hands during mid-day trading, an increase of 690% from the previous session’s volume of 671 shares. The stock last traded at $26.26 and had previously closed at $26.66.
Analyst Ratings Changes
A number of equities analysts have issued reports on WILYY shares. Sanford C. Bernstein cut Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Zacks Research downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Finally, UBS Group lowered shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Report on WILYY
Demant A/S Stock Performance
The stock’s 50-day moving average price is $23.77 and its 200-day moving average price is $20.65.
About Demant A/S
Demant A/S is a Denmark-based hearing healthcare company that develops, manufactures and distributes products and services designed to help people with hearing loss and related communication needs. Its business includes hearing aids, hearing implants, audiological diagnostic equipment, and software and technology used by hearing care professionals.
The company’s principal hearing aid brands include Oticon and Bernafon, while its portfolio also includes Philips Hearing Solutions products developed through its partnership with Koninklijke Philips.
Featured Stories
- Five stocks we like better than Demant A/S
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.
